Transfection of the antiangiogenic angiostatin and endostatin genes was shown to be an alternative to high-dose administration of angiostatin or endostatin proteins for cancer therapy. We have systematically investigated whether coadministration of the mouse angiostatin kringle 1-3 gene (pFLAG-AngioK1/3) and the endostatin gene (pFLAG-Endo) complexed with cationic liposomes exhibits enhanced therapeutic efficacy. In vitro, the coexpressed mixture of angiostatin K1-3 and endostatin more effectively reduced angiogenesis in chorioallantoic membranes than either angiostatin K1-3 or endostatin alone. In vivo, subcutaneous coadministration of pFLAG-AngioK1/3 and pFLAG-Endo lipoplexes more effectively inhibited vascularization in Matrigel plugs implanted in mice than either one alone. Additionally, subcutaneous administration of these genes inhibited the growth and formation of pulmonary metastases of B16BL6 melanoma cells in mice. Compared to treatment with an empty vector, treatment with pFLAG-AngioK1/3 plus pFLAG-Endo inhibited 81% of tumor growth, while treatment with pFLAG-AngioK1/3 or pFLAG-Endo inhibited tumor growth 70 and 69%, respectively. Cotreatment with the two plasmids after primary tumor excision induced a 90% inhibition of pulmonary metastases versus 79% for pFLAG-AngioK1/3 or 80% for pFLAG-Endo individually. These results suggest that combined administration of angiostatin K1-3 and endostatin genes complexed with cationic liposomes may be an innovated antiangiogenic strategy for cancer therapy.
A ngiogenesis is required for a variety of physiological processes such as development, wound repair, and tissue regeneration. 1 Importantly, it is also essential for the growth and persistence of solid tumors and their metastases. 2 Tumors promote angiogenesis by regulating the production of various angiogenic factors. 3 For tumor progression, expression of endogenous angiogenesis inhibitors must also be simultaneously downregulated. 4, 5 These observations suggested a rationale for the investigation of endostatin, angiostatin, salmosin, and thrombospondin-1 as candidates for the antiangiogenic therapy of cancer.
Angiostatin and endostatin are potent antiangiogenic molecules that have been extensively investigated for clinical application in anticancer therapy. 4, 7, 8 Angiostatin K1-3 is an M r 35-kDa protein with a sequence identical to the first three triple-loop structures of plasminogen 6 and endostatin is an M r 20,000 COOH-terminal fragment of collagen XVIII. 7 Unlike plasminogen and collagen XVII, angiostatin and endostatin exert their inhibitory effects on tumor progression by inhibiting endothelial proliferation, thereby indirectly affecting the growth of both tumor and non-neoplastic cells. It has been shown that administration of angiostatin and endostatin to mice carrying tumors inhibits virtually all neovascularization and causes regression of the tumors to a microscopic, dormant state. 7, 8 Additionally, a recent report demonstrating the potent antitumor activity of the combination of angiostatin and endostatin in an ovarian cancer model in mice suggested synergism between these two polypeptides. 9 Unfortunately, therapy with angiostatin and endostatin is not clinically practical because of the high doses required [7] [8] [9] [10] and the difficulty in producing them in a fully functional state. Alternatively, in vivo transfer of angiostatin or endostatin genes has been suggested as a means to provide therapeutic levels of the functionally active proteins. Studies in a mouse model have demonstrated the effectiveness of administration of viral vectors incorporating angiostatin or endostatin genes in the inhibition of tumor growth. 11 Other studies in a nude mouse and a transgenic mouse model showed that in vivo administration of liposomes complexed with plasmids encoding angiostatin or endostatin inhibits tumor progression. 12, 13 In this study, we describe the inhibition of tumor progression in a mouse model by transfection of angiostatin and/or endostatin genes. Both angiostatin and endostatin were efficiently expressed in vitro in transfected cells and in vivo in mice. In mice, subcutaneous coadministration of angiostatin and endostatin genes complexed with cationic liposomes resulted in inhibition of tumor growth and metastasis greater than that attained on treatment with the individual genes. The work reported here suggests that transfer of multiple genes with different antiangiogenic activities can be a viable strategy for anticancer gene therapy.
Materials and methods
Cell lines, animals, and reagents B16BL6 melanoma cells were obtained from Dr Isaiah J Fidler (Anderson Cancer Center, University of Texas, Houston, TX). The melanoma cells were cultured in Eagle's medium supplemented with 5% FCS, 1% nonessential amino acids, 2 mM glutamate, 1.5% vitamin solution, and 1% sodium pyruvate. Transformed human kidney cells (293 cells, ATCC: CRL-1573) were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum and 1 mM sodium bicarbonate. The cells were grown at 371C in a humidified atmosphere of 5% CO 2 . C57BL/6 mice (6-8 week-old female; 20-24 g in weight) were used for in vivo tumor inoculation. 1,2-Dioleoyl-3-(trimethylammonium) propane (DOTAP) was purchased from Avanti Polar Lipids, Inc. (Alabaster, AL). Cholesterol, anti-FLAG M2 monoclonal antibody, and anti-FLAG M2 affinity gel were purchased from Sigma Chemical Co. (St Louis, MO).
Constructs of pFLAG-AngioK1/3 and pFLAG-Endo
The cDNA, encoding the mouse plasminogen amino-acid residues 98-352 (Kringles 1-3, K1-3), was synthesized from mouse liver cDNA library by a standard polymerase chain reaction (PCR). The 5 0 primer was GGG GGTACCGTGTATCTGTCAGAATGTAAGACCG, and the 3 0 primer was GGGTCTAGAGCAGGATGGAATCT CACAGTACTC. The PCR fragment was digested with KpnI and XbaI, and cloned into the pFLAG-CMV-1 vector (KODAK, New Haven, CT) encoding the N-terminal FLAG (DYKDDDDK) epitope. The resulting construct was confirmed by DNA sequencing and designated as pFLAGAngioK1/3.
The mouse endostatin cDNA, encoding the C-terminal 183 amino acids of mouse collagen XVIII, was also amplified from mouse liver cDNA library using a PCR. The 5 0 primer was GGGAAGCTTCATACTCATCAGG ACTTTCAGC, and the 3 0 primer was GGGGGATTCC TATTTGGAGAAAGAGGTCATG. The PCR fragment was digested with HindIII and BamHI, and subcloned into the pFLAG-CMV-1 vector encoding the N-terminal FLAG epitope. The resulting construct was also confirmed by DNA sequencing and designated as pFLAGEndo.
Preparation of plasmids and cationic liposomes
The pFLAG-AngioK1/3 and pFLAG-Endo were introduced into DH5a competent Escherichia coli (Promega Inc., Woods Hollow Road, Madison, WI). The transformed cells were inoculated in LB broth for enrichment, and the plasmid DNA was purified by the alkali lysis method 14 and then stored at À201C for further use. Cationic liposomes were prepared as described previously. [15] [16] [17] DOTAP and cholesterol were mixed in chloroform 1:1 molar ratio. The chloroform was evaporated under a stream of N 2 gas. Vacuum desiccation for a minimum of 2 hours ensured removal of the residual organic solvent. The dried lipid film was hydrated with phosphate-buffered saline (PBS) or Eagle's medium. The hydrated lipids were sonicated with a bath sonicator twice for 5 minutes with a 30-minutes interval, which produced small unilamellar liposomal vesicles. The liposomes were stored at 41C.
Preparation of DNA:liposome complexes (lipoplex)
Unless otherwise indicated, plasmid DNA and liposomes were diluted in 5% dextrose solution (D5W) at a final ratio of plasmid DNA:liposome of 1:10 (wt/wt). For in vitro gene transfection, the mixture solutions were prepared in 500 ml serum-free DMEM (1 mg DNA/ml) and incubated at room temperature for 30 minutes to form stable DNA:liposome complexes. For in vivo transfection, equal volumes of both the plasmid DNA solution (4 mg/ml) and liposome solution (40 mg/ml) were mixed. The plasmid DNA solution was added rapidly at the surface of the liposome solution, which was then rapidly mixed using a pipette tip. The mixed solution was allowed to stand for 30 minutes at room temperature. The lipoplex solution was passed through a series of paired polycarbonate membrane filters (1.0, 0.45 and 0.22 mm pore size; 10 times each) using an extruder (Avanti Polar Lipids, Inc., Alabaster, AL).
In vitro transfection
The 293 transformed human kidney cells were prepared in 10-cm culture plates at a density of 1 Â 10 6 cells. After transfer into serum-free media, prepared lipoplexes were added to culture plates (10 mg of DNA per plate), which were then incubated at 371C in 5% CO 2 for 4 hours. The transfected cells were incubated for another 48 hours in the presence of serum-containing media.
In vivo gene transfection
The rapid expression of angiostatin K1-3 and endostatin genes in mice was performed by ''the hydrodynamicsbased transfection procedure'' previously reported. 18 Three groups of nine C57BL/6 mice (8-week-old female, 20-24 g in weight) were injected intravenously with 10 mg each of plasmid (pFLAG-AngioK1/3, pFLAG-Endo and pFLAG-AngioK1/3 þ pFLAG-Endo) in 2 ml saline per mouse. The plasmid DNA injection was completed in less than 5 s. The mice were bled 24 hours after injection and the expressed angiostatin K1-3 and endostatin in the mouse sera were purified through an anti-FLAG M2 affinity gel (Sigma Chemical Co., St Louis, MO) chromatography.
Western blot analysis
Culture media containing angiostatin K1-3 and endostatin expressed in vitro were collected after 48 hours of incubation and filtered through 0.22 mm filter membranes. The expressed angiostatin K1-3 and endostatin were purified by elution from an anti-FLAG M2 affinity gel. Proteins from the culture media and the eluted solutions were run on 10% SDS-polyacrylamide gel electrophoresis (PAGE) and blotted onto nitrocellulose membranes (MSI, Westborough, MA). The membranes were blocked with 5% skim milk in TBS at 371C for 1 hour and then incubated at room temperature for 30 minutes in an anti-FLAG M2 monoclonal antibody solution. The membranes were then incubated in the presence of goat antimouse IgG-horseradish peroxidase conjugate (Upstate, Lake Placid, NY) at room temperature for 30 minutes. The immunoreactive bands were stained by treatment of 3,3´-diaminobenzidine (Sigma, St Louis, MO) solution.
Chick chorioallantoic membrane assay
The antiangiogenic activity of the expressed mouse angiostatin K1-3 and endostatin was tested in a chick chorioallantoic membrane (CAM) assay. 4, 7, 19 The serumfree culture media containing angiostatin K1-3 and/or endostatin were concentrated 20-fold using M r 50,000 cutoff Amicon membranes (Amicon Inc., Beverly, MA). Fertilized eggs, 3-day-old, were carefully cracked and sealed with a transparent tape. After 3 days of incubation in 60% humidity at 371C, a methylcellulose disc containing 20 ml of the concentrated culture media was implanted on the CAM of each embryo. After 48 hours of incubation, blood vessel formation on the CAMs was observed under a stereomicroscope. 19 
Mouse matrigel plug assay
Growth factor-reduced Matrigel (11.7 mg/ml) was obtained from Becton-Dickinson (Bedford, MA). Matrigel (400 ml) was mixed with 0.1 mg of bFGF and then injected into the abdominal region of each C57BL/6 mouse. Beginning the following day, the mice were injected subcutaneously every fifth day with lipoplex (1 mg lipid and 100 mg plasmid DNA/50 ml saline) near the Matrigelinjected sites. The mice were divided into four groups (n ¼ 4): (I) saline-treated, (II) liposome:pFLAG-AngioK1/3, (III) liposome:pFLAG-Endo, and (IV) liposome:pFLAG-AngioK1/3 þ pFLAG-Endo. On the 10th day post the initial injection, the Matrigel plugs were removed and microscopic photographs of neo-blood vessels of the plugs were taken. The hemoglobin concentration in the Matrigel plugs was measured using a Drabkin kit 525 (Sigma, St Louis, MO) as described previously. 20 This assay was repeated twice.
Assay for inhibition of murine malignant tumor growth
B16BL6 mouse melanoma cells (2 Â 10 5 ) were implanted subcutaneously into the back of 6-week-old female C57BL/6 mice (n ¼ 20) as previously described. 7 The tumors were measured in two dimensions using calipers every 5th day, and their volumes were calculated as width 2 Â length Â 0.52. After the tumor volume (T/C) became approximately 100 mm 3 (0.5% of body weight), which occurred within 7 days postimplantation, the mice were randomized into four treatment regimens (n ¼ 5): (a) saline; (b) liposome:pFLAG empty plasmid, (c) liposome:pFLAG-AngioK1/3; (d) liposome:pFLAG-Endo; and (e) liposome:pFLAG-AngioK1/3 þ pFLAG-Endo. Each mouse was injected subcutaneously every 5th day with lipoplex (1 mg lipid and 100 mg DNA/50 ml saline) near the tumor sites. The tumor growth inhibition experiment was repeated twice (n ¼ 5).
Assay for inhibition of spontaneous lung metastasis of B16BL6 melanoma cells B16BL6 cells (50 ml, 2 Â 10 5 cells) were injected subcutaneously into the footpads of mice. The primary tumors were surgically removed by amputating below the knee on day 21 posttumor inoculation. The mice were then randomly divided into the four groups: (I) saline; (II) liposome:pFLAG-AngioK1/3; (III) liposome:pFLAGEndo; and (IV) liposome:pFLAG-AngioK1/3/pFLAGEndo (n ¼ 5). The lipoplex was subcutaneously administered into the dorsal midline every 5th day after removal of the primary tumors (100 mg DNA and 1 mg lipid in 50 ml saline per mouse). The mice were killed on day 35, and the extent of lung colonization was determined. The spontaneous metastasis experiment was repeated twice.
Histology
After determining colonization, the lungs were fixed in 10% neutral, buffered formaldehyde for 24 hours, transferred to 80% ethanol, and finally into 100% ethanol. The lung tissues were embedded in paraffin according to a standard histological procedure. The lung sections (5 mm thick) were stained with hematoxylin and eosin, and the sections were examined microscopically.
The lung sections were also analyzed with the von Willebrand Factor (vWF) immunocytochemistry. The rehydrated sections were incubated for 2 hours with 0.5 mg/ml rabbit anti-vWF antibody (Chemicon, Temecula, CA) and then stained with a Blood Vessel Staining Kit (Chemicon, Temecula, CA). The mean microvessel density (MVD mean ) was calculated as counts/mm 2 according to the method of Weidner. 21 
Statistical analysis
Statistical significance was analyzed by the Student's ttest. The difference between two mean values was considered as significant when the probability (P) was 0.05 or lower.
Results

In vitro and In vivo expression of angiostatin K1-3 and endostatin
In order to verify functional expression of angiostatin K1-3 and endostatin, pFLAG-AngioK1/3 or/and pFLAG-Endo were introduced into 293 cells using DOTAP/Chol-based cationic liposomes. After a 48-hour incubation of the transfected 293 cells, culture medium was collected and assayed by immunoblotting. On visualization with anti-FLAG antibody (Fig 1) bands for angiostatin K1-3 (M r 40 kDa) and endostatin (M r 28 kDa), gene products were detected in the culture medium of the singly transfected cells. Owing to the addition of the FLAG protein, these bands were located at positions a little higher than those of native angiostatin K1-3 (35 kDa) and endostatin (23 kDa). The cotransfected cells efficiently expressed the two different gene products (Fig 1, lane 4) .
The in vivo expression of the two plasmids was also tried in a mouse model using the ''hydrodynamics-based transfection'' method 18 for rapid gene expression. It is well documented that a single hydrodynamics-based transfection is able to produce sustained systemic release of administered gene products from liver cells into the bloodstream. Sera were collected 24 hours postinjection of the genes and passed through an anti-FLAG M2 affinity gel. Immunoblotting of the eluted solutions verified efficient expression of angiostatin K1-3 and/or endostatin (Fig 2, lanes 3-5) in the mice treated with the individual genes. Mice cotreated with pFLAG-AngioK1/ 3 and pFLAG-Endo efficiently expressed both gene products (Fig 2, lane 5) . Sera collected 4 weeks postinjection contained angiostatin K1-3 and endostatin at a diminished level (Fig 2, lanes 6-8) , indicating that expression was sustained at least that long.
Angiogenesis inhibition by angiostatin K1-3 and endostatin expressed in vitro
A CAM assay was carried out in order to verify the functional in vivo antiangiogenic activity of the expressed angiostatin K1-3 and endostatin. This assay system, based on developmental angiogenesis, was designed to determine if the expressed proteins had antiangiogenic activity prior to testing for their antitumor activity. The confined CAM areas on which the concentrated conditioned media containing angiostatin K1-3 and/or endostatin were applied clearly exhibited considerably reduced neovascularization compared with the other areas in close proximity (Fig 3) . Inhibition of neovascularization of the CAM by treatment with the mixture of angiostatin K1-3 and endostatin released from the cotransfected cells was far stronger than that produced by treatment with either of these alone.
Antiangiogenic activity of angiostatin K1-3 and endostatin genes transfected in vivo
To ensure that angiostatin K1-3 and endostatin derived from our plasmids possessed antiangiogenic activity, the genes were transfected into an animal model and the effects of their expression on angiogenesis were assessed by an in vivo assay. Matrigel impregnated with bFGF was implanted subcutaneously and the formation of a functional vasculature in the plugs was analyzed by measurement of the plug hemoglobin content. 20 Subcutaneous administration of angiostatin K1-3 and/or endostatin genes near the Matrigel plugs resulted in remarkable inhibition of neovascularization as indicated by low hemoglobin content (Fig 4b) and reduced vessel infiltration in the gels (Fig 4a) . Coadministration of pFLAGAngioK1/3 and pFLAG-Endo was more effective in inhibiting neovascularization in the Matrigel plugs than was administration of a single gene. Similarly, addition of angiostatin K1-3 and/or endostatin expressed in vitro to the Matrigel/bFGF mixture also inhibited angiogenesis in the Matrigel plugs (data not shown). Also, in this experiment utilizing the expressed proteins, angiogenesis was reduced significantly more in the Matrigel plugs containing angiostatin plus endostatin than in those containing angiostatin or endostatin alone. These results are consistent with the previous reports of the antiangiogenic effects of angiostatin and endostatin. 4, 7 Inhibition of B16BL6 tumor growth by administration of angiostatin K1-3 and/or endostatin genes B16BL6 mouse melanoma cells were implanted subcutaneously into the backs of C57BL/6 syngeneic mice and the mice treated with angiostatin K1-3 and/or endostatin genes every 5th day. During 3 weeks of observation, significant inhibition of growth of the primary tumor was seen in all treated mice, with tumor inhibition becoming apparent within days (Fig 5) . Coadministration of pFLAG-AngioK1/3 and pFLAG-Endo more effectively inhibited tumor growth than administration of either gene alone. Compared with pFLAG empty vector treatment, administration of the angiostatin K1-3 or endostatin genes exhibited an approximately 69-70% reduction in tumor growth by day 22 posttumor inoculation ( Fig 5) . Coadministration of angiostatin K1-3 and endostatin genes inhibited tumor growth more effectively (81% reduction at day 22) than administration of either the pFLAG-AngioK1/3 or pFLAG-Endo genes individually (Po0.05). In contrast, the primary tumors of the salinetreated and the empty vector-treated groups grew the most rapidly; attaining up to 44000 mm 3 and 43000 mm 3 volume 3 weeks postinjection, respectively.
Inhibition of B16BL6 metastasis by administration of angiostatin K1-3 and/or endostatin genes
The effect of administration of angiostatin K1-3 and/or endostatin genes on ''spontaneous'' lung metastasis of B16BL6 mouse melanoma cells was tested in an animal model. Mice were treated with liposome:pFLAG-AngioK1/3, liposome:pFLAG-Endo, or liposome:pFLAGAngioK1/3 þ pFLAG-Endo complexes. The mice treated with angiostatin K1-3 and endostatin genes exhibited the least lung colonization among the tested groups (Fig 6a,  b) . Compared with the saline control, administration of either pFLAG-AngioK1/3 or pFLAG-Endo genes resulted, respectively, in a 79% and 80% reduction in pulmonary colonization. Mice that had been cotreated with angiostatin K1-3 and endostatin genes after excision of the primary tumors exhibited a 90% reduction in pulmonary metastases. The reduction by coadministration of pFLAG-AngioK1/3 and pFLAG-Endo was statistically significant (Po0.05) from that of single administration of either gene. Histopathological analysis also demonstrated that cotreatment with these genes was the most effective in reducing tumor vascularization (Fig  6c) . The best inhibitory effect of the cotreatment on neovascularization in the metastasized tumor tissues was also supported by microvessel staining with anti-vWF antibody (Fig 6c) . The MVD mean (mean microvessel Tumor inhibition by coexpression of recombinant angiostatin K1-3 and endostatin KS Kim et al density) of pulmonary tumor tissues cotreated with angiostatin K1-3 and endostatin genes was 570.8/mm 2 , while the ones treated with angiostatin K1-3 or endostatin genes were 13.371.5/mm 2 and 10.571.3/mm 2 , respectively. The MVD mean of saline-treated pulmonary tumor tissues was the highest, that is, 29.571.3/mm 2 .
Discussion
Once solid tumors grow to more than 1-2 mm 3 in size, neovascularization of the tumor mass is required for further growth 22 and there is increasing evidence to support the hypothesis that metastasis from these tumors is facilitated by angiogenesis in the primary tumor. [23] [24] [25] The realization that solid tumors cannot expand without neovascularization has focused a major effort on evaluation of strategies employing a variety of antiangiogenesis agents. [25] [26] [27] [28] The requirements for successful antiangiogenesis therapy, such as biologic half-life sufficient to sustain tumor suppression, accessibility into the tumor area, and lack of significant interference with normal angiogenesis processes have been demonstrated by many studies.
Exogenous delivery of the antiangiogenic proteins angiostatin and/or endostatin into tumors in quantities and for the time periods sufficient to suppress tumor neovascularization is problematic. 4, 7 Hence, an alternative strategy, such as gene delivery, is needed for angiostatin or endostatin-based antiangiogenic therapy.
Recently, tests of antiangiogenic therapy employing angiostatin or endostatin genes have been conducted in animal models. [11] [12] [13] 25 In vivo expression of angiostatin or endostatin genes delivered by adenoviral vectors 11 or lipoplexes 12, 13 was clearly effective in inhibiting tumor , the mice (n ¼ 5) were treated with saline (E), pFLAG empty plasmid ('), pFLAG-AngioK1/3 (m), pFLAG-Endo ( Â ), or pFLAG-AngioK1/3 þ pFLAG-Endo (&) every 5th day. *Po0.05 versus pFLAG-AngioK1/3 or pFLAG-Endo. Figure 6 Inhibition of pulmonary metastasis of B16BL6 mouse melanoma by treatment of angiostatin K1-3 and/or endostatin genes. B16BL6 cells were subcutaneously injected into mouse the footpad. (a) The primary tumors were excised from the feet of the mice on day 21 posttumor inoculation, and the treatment then started as described in the Materials and methods. The mice were killed on day 35 and lung colonization was measured. *Po0.05 versus pFLAG-AngioK1/3 and pFLAG-Endo. (b) After measurement of lung colonization, the lungs of mice treated with saline, pFLAG-AngioK1/ 3, pFLAG-Endo, or pFLAG-AngioK1/3 þ pFLAG-Endo were photographed. (c) The lungs were fixed with 10% formaldehyde and then sectioned. The lung sections were stained with the hematoxylin and eosin reagent and observed with a microscope. Microvessles in the lung sections were also stained with anti-vWF antibody and photographed.
Tumor inhibition by coexpression of recombinant angiostatin K1-3 and endostatin KS Kim et al growth. Toxicity associated with delivery of vectors containing angiostatin or endostatin genes was not observed in most of these studies but, in one study involving administration of an adenoviral construct expressing high levels of an IgG/endostatin fusion protein, severe toxicity manifested by weight loss, bleeding, and death was observed in the recipient mice. 29 Nonviral vectors such as cationic liposomes may offer a safer alternative for in vivo transfection with angiostatin and endostatin genes and possibly other therapeutic genes as well.
We have attempted to evaluate whether cotreatment with angiostatin K1-3 and endostatin genes complexed with cationic liposomes is effective in inhibiting in vivo angiogenesis with resulting suppression of tumor progression. We constructed plasmids containing angiostatin K1-3 (pFLAG-AngioK1/3) or endostatin (pFLAGEndo) genes which were then administered as lipoplex formulations to C57BL/6 mice carrying B16BL6 mouse melanoma. Repeated administration of lipoplexes made with these genes significantly inhibited melanoma growth. Interestingly, coadministration of angiostatin K1-3 and endostatin genes inhibited tumor growth more effectively than administration of either pFLAG-AngioK1/3 or pFLAG-Endo genes singly. This implies that the two expressed proteins may function cooperatively or additively in inhibiting tumor neovascularization. Similar cooperative effects were also shown in the inhibition of pulmonary metastases of B16BL6 cells. The antiangiogenic activity of expressed angiostatin K1-3 or endostatin reduced the growth of B16BL6 tumors and, consequently, fewer pulmonary metastases resulted. We speculate that the angiostatin K1-3 and endostatin may be released from subdermal smooth muscle cells and epidermal cells after subcutaneous administration of pDNA, as reported earlier. 30 The inhibition of B16BL6 cell growth and pulmonary metastasis formation by administration of angiostatin and endostatin genes observed in this study was somewhat greater than that previously reported. Previously, Chen et al 12 reported that intratumor administration of angiostatin or endostatin genes inhibited breast cancer growth by 36 and 49%, respectively. 12 Yokoyama et al 9 reported that combination therapy with angiostatin K1-4 and endostatin proteins reduced ovarian cancer growth by 81% in athymic mice, while the reduction achieved on therapy with angiostatin or endostatin alone was 57 and 5%, respectively, indicating synergism between angiostatin and endostatin. 9 Compared with these previous reports, our data showed relatively greater inhibition of tumor growth by administration of the angiostatin and endostatin genes and a less obvious synergistic effect of the two gene products. However, as is indicated by the results of the in vivo angiogenesis assay using CAM and Metrigel, angiostatin and endostatin expressed in vitro as well as in vivo appear to be effective in synergistically or at least additively inhibiting angiogenesis. The mixture of angiostatin K1-3 and endostatin exhibited a far greater inhibition of neovascularization on CAM than either angiostatin K1-3 or endostatin alone. In addition, coadministration of the two genes was able to reduce neovascularization in Matrigel plugs implanted in mice significantly more than treatment with either gene singly.
There is no clear explanation for the observed greater inhibition of tumor growth by the combined administration of the genes and the less obvious synergy between the two gene products when compared with the previous work, but some speculations on the observed differences can be made. First, in vivo transfection of angiostatin and endostatin genes has the advantage of prolonged bioavailability of the gene products at effective levels. Continuous expression and release of these gene products from transfected cells may be more effective in maintaining these effective levels in the circulation than the exogenous administration of the proteins themselves. It is known that endostatin is rapidly cleared from the blood by renal filtration. In our hands, a single hydrodynamicsbased injection of the angiostatin and endostatin genes into mice resulted in the expression of these genes over a period of 4 weeks. Second, neovascularization induced by B16BL6 cell growth in a C57BL/6 syngeneic mouse may be more sensitive to the effects of angiostatin and endostatin than in other tumor cells in other mouse models, such as human ovarian cancer in athymic mice 9 and breast cancer-carrying transgenic mice. 13 Third, the extent and duration of gene expression may depend on specifics of the transfection system, such as the DNA vector, cationic liposome composition, and the route of administration. Last, the significant inhibition of angiogenesis by either angiostatin or endostatin may diminish their cooperative actions. We observed that early treatment with angiostatin and/or endostatin genes as mentioned previously resulted in greater, but less synergistic inhibition of B16BL6 metastasis than was observed on treatment after removal of the primary tumor.
As yet, the mechanism of enhanced inhibition of angiogenesis by the mixture of angiostatin K1-3 and endostatin is not completely clear. However, the observed synergistic (or additive) effect on tumor progression may be due to nonoverlapping antiangiogenic mechanisms. The synergism of these two antiangiogenic agents will be better understood when their downstream effectors are further elucidated. Recent reports have indicated that the reduction of Bcl-2 and Bcl-X L is observed in endostatinmediated apoptosis and that tyrosine kinase activity via the Shb adaptor protein induced by endostatin is critical to the regulation of endothelial cell apoptosis. 31, 32 Angiostatin has been shown to bind the a/b subunits of a membrane-bound ATP synthase 33 and has been shown to downregulate cell cycle regulatory proteins such as the M-phase phosphoproteins that are critical to endothelial cell proliferation. 34 Thus, it is conceivable that, if the cotransfected genes are efficiently expressed in vivo, the nonoverlapping nature of their antiangiogenic mechanisms could result in synergistically or additively enhanced inhibition of neovascularization.
We have demonstrated that angiostatin K1-3 and endostatin were effectively expressed by systemic administration of their two genes and the expressed proteins were therapeutically accessible to the experimental tumor areas. We have also demonstrated that cotransfection with angiostatin K1-3 and endostatin genes mediated by cationic liposomes is a reasonable approach to the antiangiogenic therapy of cancers. Cotransfection with an additional third antiangiogenic gene, whose action is based on a nonoverlapping mechanism, may provide further additional inhibition of tumor progression. With the advent of better gene expression systems and transfection vectors, more effective antiangiogenic gene therapy for cancer will be attainable.
